Ra Pharma's $2.1B Sale Teed Up To Close After False Starts
Biotech developer Ra Pharmaceuticals Inc. said Tuesday its $2.1 billion acquisition by Belgium's UCB will finally close this week, with the company's third submission of its merger application clearing U.S. antitrust...To view the full article, register now.
Already a subscriber? Click here to view full article